Linsitinib is highly potent, orally efficacious and highly selective, dual ATP-competitive inhibitor of IGF-1R (IC50= 35 nM) and insulin receptor (IC50=75 nM).
For research use only. We do not sell to patients.
Chemical Information
| Name | Linsitinib |
| Iupac Chemical Name | 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol |
| Synonyms | OSI 906; OSI-906; OSI906 |
| Molecular Formula | C26H23N5O |
| Molecular Weight | 421.494 |
| Smile | CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O |
| InChiKey | PKCDDUHJAFVJJB-UHFFFAOYSA-N |
| InChi | InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28) |
| CAS Number | 867160-71-2 |
| Related CAS | |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
| Bulk | | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
| Purity | 98% |
| Storage | -20 ºC for 3 years |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code | |
| Targets | |
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study | |